The McLean Laboratory has a long-standing and highly productive collaboration with Dr. Leigh Pearce in the School of Public Health at the University of Michigan. Our work together investigates factors that impact both ovarian cancer development and disease course.
Most recently, we have initiated a prospective cohort study looking at ovarian cancer survivorship, including the impact of stress on both patient well-being and clinical outcomes. This work is funded through an Investigator Initiated Research Award from the Department of Defense (DOD) Ovarian Cancer Research Program (OCRP).
Read the research
- Phung MT, et al. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecol Oncol. 2023 Jan;168:68-75. doi: 10.1016/j.ygyno.2022.10.018.
- Brieger KK, et al. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):443-452. doi: 10.1158/1055-9965.EPI-21-0977.
- Khoja L, et al. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecol Oncol. 2022 Jan;164(1):195-201. doi: 10.1016/j.ygyno.2021.10.088.
- Phung MT, et al. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. doi: 10.1158/1055-9965.EPI-20-1355.
- Brieger KK, Pet al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol. 2020 Sep;158(3):702-709. doi: 10.1016/j.ygyno.2020.06.481.
Contact the McLean Laboratory
Department of Gynecology
Department of Pharmacology & Therapeutics
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263